论文部分内容阅读
在发展中国家,关于肺结核病治疗方法的价值,仍在争论不休。我们对马拉维(Malawi)、莫桑比克和坦桑尼亚三个国家采用化学疗法治疗痰液涂片阳性的肺结核病的成本效果进行了研究。短期化学疗效为86～90%,常规化学疗法疗效为60～66%。住院短期化疗病人每延长一年寿命的平均费用增加额为1.7～2.1美元;住院常规化疗为2.4～3.4美元;不住院短期化疗为0.9～1.1美元,不住院常规化疗为0.9～1.3美元。
In developing countries, the value of treatment methods for tuberculosis is still arguing. We studied the cost effectiveness of using chemotherapy to treat sputum smear-positive tuberculosis in three countries in Malawi, Mozambique and Tanzania. The short-term chemical efficacy is 86-90%, and the conventional chemotherapy is 60-66%. The average increase in the cost per one-year extension of hospitalized short-term chemotherapy patients is 1.7 to 2.1 US dollars; the conventional hospital chemotherapy is 2.4 to 3.4 US dollars; the non-hospital short-term chemotherapy is 0.9 to 1.1 US dollars, and the non-inpatient routine chemotherapy is 0.9 to 1.3 US dollars.